Co-Diagnostics Reports Shareholder Vote Matters

TL;DR

CDXC shareholders voted on key company matters; details filed.

AI Summary

Co-Diagnostics, Inc. filed an 8-K on August 30, 2024, reporting on matters submitted to a vote of security holders as of August 29, 2024. The filing details corporate actions and decisions requiring shareholder approval, as is standard for such reports.

Why It Matters

This filing indicates that Co-Diagnostics, Inc. is engaging in corporate governance processes that involve shareholder decision-making, which can impact the company's strategic direction and operations.

Risk Assessment

Risk Level: low — This is a routine corporate filing regarding shareholder votes, not indicating immediate financial distress or significant operational changes.

Key Players & Entities

• Co-Diagnostics, Inc. (company) — Filer of the 8-K report
• August 29, 2024 (date) — Date of the earliest event reported
• August 30, 2024 (date) — Date of report filing
• Utah (location) — State of incorporation

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share CODX The Nasdaq Capital M

Filing Documents

• form8-k.htm (8-K) — 48KB
• 0001493152-24-034599.txt ( ) — 217KB
• codx-20240829.xsd (EX-101.SCH) — 3KB
• codx-20240829_lab.xml (EX-101.LAB) — 33KB
• codx-20240829_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 4KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 29, 2024 CO-DIAGNOSTICS, INC. (Exact name of small business issuer as specified in its charter) Utah 1-38148 46-2609363 (State or other jurisdiction of (Commission (IRS Employer incorporation or organization) File Number) Identification Number) 2401 S. Foothill Drive , Suite D , Salt Lake City , Utah 84109 (Address of principal executive offices) (801) 438-1036 (Issuer's telephone number) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share CODX The Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.07 Submission of Matters to a Vote of Security Holders On August 29, 2024, Co-Diagnostics, Inc. (the "Company"), held its 2024 annual meeting of shareholders at which the following matters were voted on: Proposal No. 1 : Election of Directors. The Company's shareholders elected for a three-year term one person nominated for election as a director. The following table sets forth the vote of the shareholders at the meeting with respect to the election of directors: Nominee Votes For Votes Withheld Broker Non-votes James Nelson 6,684,070 4,008,945 4,376,742 There were no abstentions with respect to the election of directors. Proposal No. 2 : A proposal to adopt, on an advisory basis, a non-binding resolution approving the compensation of the Company's named executive officers, as described in the Proxy Statement under "Executive Compensation." This proposal was adopted. For Against Abstain Broker Non-votes 9,312,471 1,279,949 100,595 4,376,742 Proposal No. 3 : Frequency of Future Advisory Votes to Approve Executive Compensation. The Company's shareholders voted upon and adopted a non-binding resolution approving the frequency of One Year (an annual vote) for the frequency of future advisory votes relating to the compensation of the Company's named executive officers: One Year 2 Years 3 Years 4 Years 10,235,779 120,759 199,580 136,897 Proposal No. 4 : A proposal to ratify the Audit Committee's appointment of Tanner LLC as the Company's independent registered public accounting firm for the year ending December 31, 2024. This proposal was ratified. For Against Abstain Broker Non-vote 13,285,933 1,742,178 41,646 - SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CO-DIAGNOSTICS, INC. Date: August 30, 2024 By: /s/ Brian Brown Name: Brian Brown Title: Chief Financial Officer (Principal Financial and Accounting Officer)

View Full Filing

View this 8-K filing on SEC EDGAR